Diabetes Attenuates the Contribution of Endogenous Nitric Oxide but Not Nitroxyl to Endothelium Dependent Relaxation of Rat Carotid Arteries

Jasmin Chendi Li1,2,3†, Anida Velagic1,2†, Cheng Xue Qin1,2,3*, Mandy Li1,4, Chen Huei Leo5, Barbara K. Kemp-Harper6, Rebecca H. Ritchie1,2,3,4 and Owen L. Woodman1,2

1Drug, Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia, 2Baker Heart & Diabetes Institute, Melbourne, VIC, Australia, 3Department of Pharmacology, University of Melbourne, Parkville, VIC, Australia, 4Department of Pharmacology, Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia, 5Science, Maths and Technology Cluster, Singapore University of Technology & Design, Singapore, Singapore.

Introduction: Endothelial dysfunction is a major risk factor for several of the vascular complications of diabetes, including ischemic stroke. Nitroxyl (HNO), the one electron reduced and protonated form of nitric oxide (NO•), is resistant to scavenging by superoxide, but the role of HNO in diabetes mellitus associated endothelial dysfunction in the carotid artery remains unknown.

Aim: To assess how diabetes affects the role of endogenous NO• and HNO in endothelium-dependent relaxation in rat isolated carotid arteries.

Methods: Male Sprague Dawley rats were fed a high-fat-diet (HFD) for 2 weeks prior to administration of low dose streptozotocin (STZ; 35 mg/kg i. p./day) for 2 days. The HFD was continued for a further 12 weeks. Sham rats were fed standard chow and administered with citrate vehicle. After 14 weeks total, rats were anesthetized and carotid arteries collected to assess responses to the endothelium-dependent vasodilator, acetylcholine (ACh) by myography. The combination of calcium-activated potassium channel blockers, TRAM-34 (1 μmol/L) and apamin (1 μmol/L) was used to assess the contribution of endothelium-dependent hyperpolarization to relaxation. The corresponding contribution of NOS-derived nitrogen oxide species to relaxation was assessed using the combination of the NO• synthase inhibitor, L-NAME (200 μmol/L) and the soluble guanylate cyclase inhibitor ODQ (10 μmol/L). Lastly, l-cysteine (3 mmol/L), a selective HNO scavenger, and hydroxocobalamin (HXC; 100 μmol/L), a NO• scavenger, were used to distinguish between NO• and HNO-mediated relaxation.

Results: At study end, diabetic rats exhibited significantly retarded body weight gain and elevated blood glucose levels compared to sham rats. The sensitivity and the maximal relaxation response to ACh was significantly impaired in carotid arteries from diabetic rats, indicating endothelial dysfunction. The vasorelaxation evoked by ACh was abolished by L-NAME plus ODQ, but not affected by the apamin plus TRAM-34 combination, indicating...
that NOS-derived nitrogen oxide species are the predominant endothelium-derived vasodilators in sham and diabetic rat carotid arteries. The maximum relaxation to ACh was significantly decreased by L-cysteine in both sham and diabetic rats, whereas HXC attenuated ACh-induced relaxation only in sham rats, suggesting that diabetes impaired the contribution of NO•, whereas HNO-mediated vasorelaxation remained intact.

**Conclusion:** Both NO• and HNO contribute to endothelium-dependent relaxation in carotid arteries. In diabetes, NO•-mediated relaxation is impaired, whereas HNO-mediated relaxation was preserved. The potential for preserved HNO activity under pathological conditions that are associated with oxidative stress indicates that HNO donors may represent a viable therapeutic approach to the treatment of vascular dysfunction.

**Keywords:** nitric oxide, nitroxyl, Diabetes, endothelium, carotid arteries, nitroxyl mediated relaxation in diabetes

**INTRODUCTION**

Diabetes is a metabolic disease associated with progressive damage to the vascular wall, which can promote the development of macrovascular and microvascular complications (Stratton et al., 2006; Cade, 2008; Fowler, 2008; Fatehi-Hassanabad et al., 2010). The hallmark of these vascular complications is the development of endothelial dysfunction and increased reactive oxygen species (ROS) production (Schalkwijk, 2005; Sharma et al., 2012). This is characterized by reduced production of endothelium-derived relaxing factors including prostacyclins (Moncada et al., 1976), nitrogen oxide species such as nitric oxide (NO•) (Palmer et al., 1988) and a non-NO•/non-prostanoid mediator of endothelium-dependent hyperpolarization (EDH, previously associated with the definition of endothelium-derived hyperpolarizing factors) (Coleman et al., 2017; Garland and Dora, 2017; Leung and Vanhoutte, 2017). In addition, endothelial dysfunction is associated with atherosclerotic plaque formation, which can lead to arterial stenosis and thrombosis (Endemann and Schiffrin, 2004; Sitia et al., 2010; Zardi and Afeltra, 2010). Atherothrombotic occlusion is more prevalent in large arteries, such as carotid arteries, rather than smaller, resistance vessels. Thus, carotid artery stenosis is widely used to predict the likelihood of stroke (Dempsey et al., 2010; Kwee et al., 2013) and carotid plaque formation (Spagnoli et al., 2004; Ding et al., 2008). Given the relationship between endothelial dysfunction, atherosclerosis, and ischemic stroke, it is likely that the extent of endothelial dysfunction in the carotid vasculature may reflect the risk of an individual developing ischemic cerebrovascular disease.

There are multiple mechanisms of endothelium-dependent relaxation including via endogenous NO• (Palmer et al., 1988), HNO, the one-electron reduced and protonated form of NO• (Dutton et al., 2004; Andrews et al., 2009; Bullen et al., 2011), the arachidonic acid metabolite prostacyclin (Moncada et al., 1976) and EDH, which causing hyperpolarization in the smooth muscle layer and affecting conducted vasodilation in arteries (Coleman et al., 2017; Garland and Dora, 2017; Leung and Vanhoutte, 2017). Importantly, like NO•, there is evidence to suggest that HNO is endogenously generated and serves as an endothelium-derived vasodilator in both conduit and resistance arteries (Ellis et al., 2000; Andrews et al., 2009; Bullen et al., 2011; Leo et al., 2012; Tare et al., 2017). While there are a range of chemical reactions that may lead to the endogenous synthesis of HNO (Marti et al., 2017), the strongest body of evidence indicates it is synthesized as a co-product of endothelial nitric oxide synthase (eNOS) during the conversion of L-arginine to NO• (Stoll et al., 2010; Paolocci et al., 2016; Marti et al., 2017). Importantly, it has also been shown that where eNOS is uncoupled due to oxidative stress or where there is a deficiency of the cofactor, tetrahydrobiopterin (BH4), the production of HNO by eNOS is promoted over NO• (Fukuto et al., 1992; Rusche et al., 1998; Adak et al., 2000; Tantillo et al., 2000). Thus, in disease states, where eNOS is uncoupled, HNO may be generated. While it is well established that diabetes has a detrimental effect on endothelial function which then contributes to diabetes-induced morbidity and mortality due to cardiovascular disease, it is less well established how the different mechanisms of endothelium-dependent relaxation are individually impacted. It is however clear that diabetes impairs NO• mediated relaxation associated with diabetes-induced oxidative stress. Unlike NO•, HNO is resistant to scavenging by reactive oxygen species (ROS) such as superoxide (O2−) (Miranda et al., 2002; Leo et al., 2012), suggesting that the actions of HNO may be preserved in diabetes and HNO may be able to compensate for impaired NO•-mediated signaling. Our previous studies have shown that HNO is preserved in the diabetic aorta (Leo et al., 2012), femoral and mesenteric arteries (Kahlberg et al., 2016; Tare et al., 2017) however it is unknown if this is also the case in the carotid artery, a clinically important blood vessel given the prevalence of carotid artery stenosis and stroke in patients with diabetes.

There are contradictory findings in regard to the impact of diabetes on EDH-mediated vascular relaxation with some reports that relaxation is impaired (Kamata et al., 2000; Wigg et al., 2001; Matsumoto et al., 2003; Leo et al., 2011; Matsumoto et al., 2017) contrasted by others that EDH relaxation is maintained (Kagota et al., 2011; Cho et al., 2013; Makhtar et al., 2016a) or even...
enhanced in human subcutaneous arteries (Mokhtar et al., 2016b). Although EDH does not make a significant contribution to endothelium-dependent relaxation in carotid arteries under non-disease conditions, there is evidence that it may be upregulated early in the development of diabetes (Leo et al., 2010; Centeno et al., 2019) and there is an associated increase in IKCa (Kagota et al., 2011; Schach et al., 2014). As such when considering the interplay between endothelium-derived relaxing factors in diabetes, it is important to evaluate the role of NO•, EDH and HNO.

It remains unclear whether endogenous HNO-mediated vasorelaxation and the release of basal HNO is affected by diabetes-induced endothelial dysfunction in conduit vessels such as the carotid arteries. We hypothesized that basal and stimulated release of endogenous HNO is preserved, whereas endothelial function is impaired, in diabetic rat carotid arteries. Therefore, this study aims to characterize the relative contribution of NO• and HNO to endothelium-dependent relaxation in rat carotid arteries both in terms of their basal and stimulated release.

MATERIALS AND METHODS

Animal Model

All animal research and procedures involved in this project were conducted in accordance with the National Health and Medical Research Council of Australia Code of Practice for the Care and Use of Animals for Scientific Purposes and approved by the Alfred Medical Research Educational Precinct (AMREP) Animal Ethics Committee (AEC; under the ethics approval number: E/1759/2017/B). Male Sprague Dawley (SD) rats were bred and housed within the AMREP precinct animal center at an ambient temperature of 22°C, with a 12-h light/dark cycle. At 8 weeks of age, pre-adolescent male SD rats (n = 39; body weight: 200–350 g) were randomly allocated to one of two groups, sham or diabetic. Rats were fed an HFD (SF03–002, 36% fat and 19.4% protein with total 59% digestible energy intake from lipids, Specialty Feeds, WA, Australia) (Marsh et al., 2009) for two weeks, after which the rats were administered two low-doses of streptozotocin (STZ, 24 h apart, each 35 mg/kg i.p., in 0.1 mol/L citrate, pH4.5, n = 20). The HFD then continued for a further 12 weeks. The sham group received two injections of vehicle (24 h apart, 0.1 mol/L citrate vehicle, pH 4.5) and were fed standard laboratory chow (n = 19). Throughout the 14-weeks study period, blood samples were collected fortnightly through a small cut on the tail end and blood glucose levels were assayed by a one-touch glucometer (Roche, Sydney, NSW, Australia). The upper limit of detection of the glucometer was 33.3 mmol/L. Hence, any reading above this point was recorded as 33.3 mmol/L (Ritchie et al., 2012). One week following STZ administration, diabetic rats with blood glucose levels exceeding 28 mM received subcutaneous insulin (1–2 U as required, Humulin NPH, Lilly) to prevent complications of severe hyperglycemia. At 21 weeks of age, a glucose tolerance test (GTT) was performed. To perform the GTT, after a 6 h fast, the animals were injected with 3 ml/kg body weight of glucose solution (10% glucose w/v, i.p.) and blood glucose levels were measured at 0, 15, 30, 45, 60, 90 and 120 min via the tail vein. Body composition was determined using an EchoMRI 3-in-1 Body Composition Analyzer (Echo Medical Systems, Houston, TX, USA) to determine the body composition according to the manufacturer’s protocol. Blood glucose and glycated hemoglobin (HbA1c) levels were measured before exsanguination, using the one-touch glucometer and a Cobas Hba1c analyser (Roche, Sydney, NSW, Australia), respectively. Any reading is shown as "Low", was recorded as 3% as the lower limit of detection of the HbA1c analyser (Genc et al., 2012). Rats were then anesthetized by a combined dose of ketamine and xylidine (100 and 20 mg/kg, respectively, i.p.). Once anesthetized, whole blood was collected from the hepatic vein for further measurement of plasma insulin, and animals were euthanized by exsanguination (Hickman and Johnson, 2011). Both carotid arteries were collected for myography experiments. Plasma insulin was measured using commercially available Rat Ultrasensitive Insulin ELISA kits (ALPCO, Salem, NH, USA) (French et al., 2017) according to the manufacturer’s instructions.

Myograph Experiments

Isolation and Equilibration of Rat Carotid Arteries

Carotid arteries were isolated and immediately placed in ice-cold Krebs’ solution (in mmol/L: 120 NaCl, 5 KCl, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 11.1 d-glucose and 2.5 CaCl2). Indomethacin (10 µmol/L), a non-selective cyclooxygenase inhibitor, was added to the Krebs’ solution to prevent the synthesis of prostanooids by the artery segments in all studies, as described previously (Leo et al., 2010; Kahlberg et al., 2016). Carotid arteries were cleared of all loose connective tissue and fat and cut into two- to 3-mm ring segments. Each ring was mounted on a myograph (model 610M, Danish Myo Technology, Aarhus, Denmark) containing Krebs’ solution gassed with carbogen (95% O2 and 5% CO2) at 37°C. After the arteries were mounted on the myograph, they were adjusted to a passive tension of 15 mN, which was continuously recorded using LabChart 8 Pro software (ADInstruments, Hastings, United Kingdom). Twenty minutes after equilibration, Krebs’ solution was replaced with a high K+-containing physiological saline solution (KPSS in mmol/L: KCL 1.25, MgSO4 1.2, KH2PO4 1, NaHCO3 25, d-glucose 11.1, CaCl2 2.5) for 20 min to induce maximal contraction (Supplementary Table S2). Vessels were then rinsed with Krebs’ solution and allowed to regain basal tension. Arteries were then precontracted to 50–70% of their maximal contraction to KPSS, using PE (0.01–1 µmol/L) in all studies. In a limited number of experiments, the thromboxane A2 receptor agonist 9, 11-dideoxy-9a, 11a-methanoepoxy-PGF2α (U-46619; 1–10 nmol/mL) was also added when arteries failed to reach optimal stable contraction with PE alone, as previously described (Kahlberg et al., 2016; Leo et al., 2020) (Supplementary Table S2). Endothelial integrity was determined by exposure to a single concentration of acetylcholine (ACh 10 µmol/L), with relaxation >80% of pre-constriction levels accepted as indicative of a functionally intact endothelium.
Assessment of Vascular Reactivity Ex Vivo

After further rinses and recovery of basal tension, arteries were again pre-contracted to 50–70% of the maximum contraction (KPSS response) using phenylephrine (PE; 0.01–1 μmol/L) either alone or in combination with U-46619 (1–10 nmol/L). The effects of different treatments on relaxation responses in carotid arteries were assessed via cumulative concentration-response curves to the endothelium-dependent vasodilator, ACh (0.1–10 μmol/L) and the endothelium-independent vasodilator, sodium nitroprusside (SNP; 0.1 nmol/L-10 μmol/L). Responses to ACh and SNP were also examined following 20 min incubation with different combinations of N^2-nitro-l-arginine methyl ester (L-NAME; 200 μmol/L, a NOS inhibitor); 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; 10 μmol/L, a soluble guanylate cyclase (sGC) inhibitor); apamin (1 μmol/L, small-conductance Ca^{2+}-activated K⁺ channel (SK Ca) blocker); and 1-(2-chlorophenyl) (diphenyl)methyl-1H-pyrazole (TRAM-34; 1 μmol/L, a selective intermediate-conductance Ca^{2+}-activated K⁺ channel (IK Ca) blocker). In addition, the K Ca channel blockers were also incubated either alone or in combination with L-cysteine (3 mmol/L), a selective HNO scavenger, or hydroxocobalamin (HXC), a selective NO• scavenger (100 μmol/L), as described previously (Ritchie et al., 2013; Marshall et al., 2020).

Assessment of Basal Nitrogen Oxide, NO• and HNO Activity Ex Vivo

In another set of myograph experiments, the impact of diabetes on the basal release of eNOS-derived nitrogen oxides were determined. Endothelium-intact carotid artery rings were sub-maximally precontracted to ~20% of the KPSS response with PE (10–100 nmol/L) (Supplementary Figures S2, S3). After stabilization of contraction, carotid artery rings were either exposed to L-NAME (200 μmol/L), L-cysteine (3 mmol/L) or HXC (100 μmol/L) (Leo et al., 2011; Kahlberg et al., 2016). Under these conditions, contractile response to L-NAME was considered to reflect the level of basal eNOS-derived nitrogen oxides (NO• and HNO). The contractile response to L-cysteine or HXC were considered to reflect the basal level of HNO or NO•, respectively.

Reagents

All reagents were purchased from Sigma-Aldrich (St Louis, MO, USA) except for ODQ and U46619 (Cayman Chemical, Ann Arbor, MI, USA), and all compounds used were of analytical grade or higher. Aliquots of drugs were dissolved in distilled water and stored at ~20°C, except indomethacin, which was dissolved in 0.1 mol/L sodium bicarbonate, as well as both ODQ and TRAM-34, which were dissolved in 100% dimethyl sulfoxide (DMSO, final concentration less than 0.1%), and U-46619, which was dissolved in absolute ethanol as a 1 mM stock solution, with subsequent dilutions in distilled water.

Statistical Analysis

All data are expressed as mean ± SEM, where n is the number of animals per group. Individual concentration-response curves from rat isolated carotid arteries were computer-fitted to a sigmoidal logistical equation using non-linear regression (GraphPad Prism 7.0 Software, CA, USA) to calculate the log_{10} of the concentration of each agonist causing a 50% relaxation (pEC_{50} mol/L). Maximum relaxation (R_{max}) evoked by ACh and SNP were expressed as a percentage reversal of the precontraction to phenylephrine and/or U46619. Group pEC_{50}, R_{max} and systemic characteristics were compared using Student’s t-test or one-way ANOVA followed by a post-hoc Dunnett’s test as appropriate. Body weights and blood glucose levels were analyzed using a two-way ANOVA with Sidak’s post-hoc analysis for multiple comparisons. p values of <0.05 were considered statistically significant.

RESULTS

Systemic Characteristics In Vivo

Twelve weeks after STZ or vehicle administration and fourteen weeks after commencing HFD or standard laboratory diet, weight gain was evident in both groups, however, diabetic rats exhibited significantly lower body weight (Figure 1A) and fat mass (Figure 1D) than sham rats at end point, indicative of retarded body weight gain. Both blood glucose levels and HbA1c of diabetic rats were significantly greater than those of sham rats (Figure 1B,E).

Glucose Tolerance Test and Plasma Insulin Level

To determine the level of glucose tolerance a GTT was performed during the final week of the study. Blood glucose levels of both sham and diabetic rats increased following an i. p. injection of glucose (3 ml/kg, 10% glucose w/v) (Figure 1C). In sham rats, the maximal rise in blood glucose concentration was evident 15 min post-injection but returned to baseline within 90 min of glucose administration. In contrast, blood glucose concentration remained elevated in diabetic rats throughout the test and did not return to baseline at test completion (120 min post-injection). These findings suggest that glucose tolerance is impaired in the diabetic group. Serum insulin concentrations measured at study endpoint did not differ significantly between the two groups (Figure 1F).

Effect of Diabetes on Relaxation to Acetylcholine and Sodium Nitroprusside

Relaxation responses to ACh and SNP in carotid arteries from sham and diabetic rats are shown in Figure 2. Diabetes significantly reduced the sensitivity and maximal relaxation to ACh compared to sham (Figure 2A, Table 1). However, the relaxation to the endothelium-independent vasodilator SNP was not significantly different between the two groups (Figure 2B, Table 1), suggesting that there was a selective impairment of endothelial function in the carotid arteries from diabetic rats.
FIGURE 1 | Systemic characteristics in vivo. Body weight (A) and blood glucose level (B) of sham (■) and diabetic (●) rats thought out the study period. The Blood glucose level of sham (■) and diabetic (●) rats throughout the glucose tolerance test (C). Fat mass (D), % HbA1c (E) and serum insulin level (F) of sham (blue bar) and diabetic (red bar) groups at the end of the experimental period. Body weight and blood glucose level (Two-way ANOVA with Sidak’s multiple comparisons test); Fat mass, % HbA1c and serum insulin level (Unpaired Student’s t-test); Glucose tolerance test (Two-way ANOVA with Tukey’s multiple comparisons test). Diabetic n = 20; sham n = 19 experiments. Values are mean ± SEM *p < 0.05, **p < 0.01, ***p < 0.0001 vs sham animals. #p < 0.05, ####p < 0.0001 vs. zero time point.

FIGURE 2 | Cumulative concentration-response curves to ACh and SNP. Acetylcholine (A) (n = 14–16) and sodium nitroprusside (B) (n = 14–16) in isolated carotid arteries from sham (■) and diabetic (●) rats. Indomethacin (10 µM) was always present in the Krebs’ buffer. Values are shown as mean ± SEM, where n = number of animals. pEC50 *p < 0.05 vs sham animals, Rmax #p < 0.05 vs sham animals (Unpaired Student’s t-test). See Table 1 for pEC50 and Rmax values.
Impact of Diabetes on the Relative Contribution of EDH and NOS-Derived Nitrogen Oxide Species to ACh-Evoked Relaxation

Vascular reactivity to ACh was further assessed in the presence of either the combination of small and intermediate conductance Ca$^{2+}$ activated K$^+$ channel blockers (apamin and TRAM-34, respectively), or the combination of l-NAME and ODQ to determine the relative contribution of EDH and NOS-derived nitrogen oxide species, respectively, to endothelium-dependent relaxation in sham and diabetic rat carotid arteries (Figure 3, Table 1). In carotid arteries from both sham and diabetic groups, ACh-induced relaxation was not affected by the presence of apamin and TRAM-34, but virtually abolished by the combination of l-NAME and ODQ, indicating that a NOS-derived nitrogen oxide species is the predominant endothelium-derived vasodilator in carotid arteries rather than EDH (Figures 3A,B, Table 1). Furthermore, in carotid arteries from all groups, the relaxation response to ACh was completely abolished in the presence of apamin, TRAM-34, l-NAME and ODQ combined, which suggests that there was no contribution of non-nitrogen oxide species/non-EDH to relaxation (Figures 3A,B, Table 1).

**Effect of Diabetes on the Relative Contribution of Endothelium-Derived NO• and Nitroxyl to Endothelium-Dependent Relaxation**

In order to determine the contribution of endothelium-derived NO• vs. HNO to relaxation in the carotid artery, the EDH component of endothelium-dependent relaxation was eliminated with KCa blockers (apamin + TRAM-34). Under these conditions, the relaxant response to ACh in the presence of HXC (NO• scavenger) or L-cysteine (HNO scavenger) is

---

**TABLE 1 | Pharmacological parameters of endothelial function ex vivo.** A comparison of sensitivity (pEC50) and maximum relaxation (Rmax) to ACh or SNP in the absence or presence of various inhibitors in endothelium-intact carotid arteries isolated from sham and diabetic rats. All experiments were conducted in the presence of indomethacin (10 µmol/L). n = the number of experiments. Results are given as mean ± SEM. *p < 0.05 vs. sham, one-way ANOVA with Dunnett’s post-hoc test. ND: not determined.

| ACh | n | pEC50 | Rmax (%) | Diabetic | n | pEC50 | Rmax (%) |
|-----|---|-------|----------|----------|---|-------|----------|
| Control | 14 | 7.24 ± 0.15 | 96 ± 1 | 16 | 6.72 ± 0.18* | 90 ± 3* |
| Apamin + TRAM 34 | 13 | 6.82 ± 0.22 | 93 ± 2 | 16 | 6.43 ± 0.16 | 88 ± 3 |
| l-NAME + ODQ | 6 | ND | 22 ± 8* | 7 | ND | 17 ± 8*** |
| Apamin + TRAM 34 + l-NAME + ODQ | 6 | ND | 9 ± 8*** | 5 | ND | 13 ± 8*** |
| Apamin + TRAM 34 + l-cysteine | 6 | 6.77 ± 0.66 | 62 ± 8*** | 8 | 6.55 ± 0.26 | 60 ± 12*** |
| Apamin + TRAM 34 + HXC | 7 | 6.50 ± 0.17 | 72 ± 11* | 8 | 6.44 ± 0.23 | 84 ± 6 |
| SNP | 6 | ND | 22 ± 7*** | 7 | ND | 7N D ± 7#### |

**FIGURE 3 | Relative contribution of EDH and NOS-derived nitrogen species to ACh-induced Relaxation in rat carotid arteries.** Cumulative concentration response curves to ACh in the absence (control) and presence of either apamin + TRAM 34 (n = 6), l-NAME + ODQ (n = 6–7) and apamin + TRAM 34 + l-NAME + ODQ (n = 6). Carotid arteries isolated from (A) Sham (B) Diabetic rats. Indomethacin (10 µM) was always present in the Krebs’ buffer. Values are mean ± SEM, where n = number of animals. ##Rmax vs control (p < 0.0001, one-way ANOVA, Dunnett’s post-hoc test). See Table 1 for pEC50 and Rmax values.
mediated by HNO or NO•, respectively. In sham carotid artery, the maximum relaxation response to ACh was significantly attenuated either by the presence of the NO• scavenger, HXC, or the HNO scavenger, l-cysteine (Figure 4A, Table 1). Thus NO• and HNO both contributed to endothelium-dependent relaxation in the carotid arteries from sham rats. In contrast, in carotid arteries from diabetic rats, there was a significant decrease in the Rmax to ACh in the presence of the HNO scavenger, l-cysteine, but not the NO• scavenger, HXC (Figure 4B, Table 1), indicating that NO•-mediated endothelium-dependent relaxation was impaired by diabetes whereas HNO-mediated relaxation was intact.

### Impact of Diabetes on Basal Levels of Nitrogen Oxide/NO•/Nitroxyl Bioavailability

Diabetes did not affect the maximum contraction to KPSS (125 mmol/L) (Supplementary Figure S1). Similarly, l-NAME induced arterial contraction, attributed to the basal release of nitrogen oxides, was not significantly different between the two groups (Figure 5A). In contrast, the HXC-induced contraction, which reflected the basal level of NO•, was significantly reduced in carotid arteries from diabetic compared to sham rats (Figure 5B, p < 0.005). Furthermore, the contractile responses to l-cysteine, attributed to the basal level of HNO, was not significantly different in carotid arteries from diabetic compare to sham rats (Figure 5C). Together these findings suggest that the basal activity of endogenous NO• is reduced by diabetes whereas the basal release of HNO is preserved.

### Effect of Diabetes on the Relative Contribution of NO• and Nitroxyl to Sodium Nitroprusside-Induced Relaxation

As indicated previously, diabetes had no the effect on relaxation response to SNP (Figure 2B, Table 1). The relative contribution of NO• and HNO to the endothelium-independent, SNP-induced relaxation in the carotid artery was examined. Similar to the assessment of endothelium-dependent relaxation, the EDH component was eliminated with KCa blockers (apamin + TRAM-34). The sensitivity, but not maximum relaxation response was significantly impaired by the presence of either a NO• scavenger (HXC with KCa blockers) or a HNO scavenger (l-cysteine with KCa blockers) in carotid arteries from both sham and diabetic rats.
which demonstrated that both NO and HNO contribute to relaxant responses to SNP and diabetes did not impair the responses to either of these mediators when released from SNP rather than the endothelium.

We then looked the contribution of sGC in SNP-mediated relaxation in carotid arteries from sham or diabetic vessels. The response to SNP could almost be abolished either by the presence of apamin + TRAM-34 or at least cysteine or HXC in a concentration-dependent manner (Figures 7A, Table 1) in carotid arteries from sham and diabetic rats (Figure 7B, Table 1), indicating that nitrogen oxide species largely acts on sGC.

**DISCUSSION**

Diabetes is a known risk factor for stroke, a component of stroke risk is likely associated with diabetes-induced endothelial dysfunction (Sitia et al., 2010; Douglas and Channon, 2014). In this study, the endothelial function of carotid arteries, as well as the endothelium-derived nitrogen oxide-mediated relaxation was assessed in diabetic rats. Rats that received the HFD and two low-doses of STZ exhibited hyperglycaemia, elevated HbA1c and reduced glucose tolerance. Endothelial dysfunction was evident in the carotid artery of diabetic rats, which was mainly due to a decreased contribution of NO-mediated relaxation, whereas the contribution of HNO was maintained. There was no evidence of an EDH contribution to endothelium-dependent relaxation of carotid arteries from either control or diabetic rats. Diabetes also caused a decrease in basal NO bioavailability in carotid arteries, but the basal HNO release was preserved (Figure 8). Our study demonstrated for the first time that although there was selective impairment of endothelial function, the stimulated and basal release of HNO was preserved in the carotid artery of diabetic animals.

T2DM is a complex metabolic disorder essentially characterized by insulin resistance and a defect in pancreatic β-cell mass and function, and that is strongly influenced by lifestyle and diet (Guilherme et al., 2008; Podell et al., 2017;
Ritchie and Abel, 2020). Previous studies have indicated that an animal model that incorporates an HFD to induce peripheral insulin resistance (Sankar et al., 2012; Podell et al., 2017; Sampath et al., 2017), is often associated with limited end-organ damage. Additional low dose STZ administration with HFD only destroys a portion of (not all) the pancreatic β-cells to increase plasma glucose moderately. This phenotype closely mimics the pathogenesis of human T2DM (Reed et al., 2000; Asrafuzzaman et al., 2017). The HFD + low dose STZ approach has been gaining popularity in recent years, providing an alternative to the existing genetic model of T2DM (e.g. db/db mice, Zucker rats). This model was first reported by the Reed group (Reed et al., 2000), where they have demonstrated that rats that were fed an HFD exhibited high blood insulin levels but essentially normal blood glucose concentrations. The additional low dose of STZ injection led to mild impairment in insulin secretion, closely resembling the key characteristics of insulin resistance and pancreatic β-cell dysfunction in human T2D. Since then, different combinations of diet and STZ dosage have been developed.

In the present study, we have adopted a model similar to Marsh et al. (Marsh et al., 2009), using a combination of HFD (SF03-002; total digestible energy: 59% lipids, 15% protein; wt/ wt: 34.6% sucrose; Specialty Feeds, WA, Australia) and two low-dose injections of STZ (30 mg/kg, 24-h apart). Our model of HFD/STZ rats exhibited hyperglycaemia and elevated HbA1c, which was apparent as early as 2 weeks following the second injection of STZ. Accompanying this hyperglycaemia, the rats displayed many characteristics of T2DM including reduced glucose tolerance and retarded weight gain, which are consistent with previous studies where an HFD was combined with multiple low-doses of STZ in rats (Zhang et al., 2008; Albersen et al., 2011). The combination of elevated plasma glucose but with a maintained plasma insulin level in these HFD/STZ rats is consistent with insulin resistance (Reed et al., 2000; Sharma et al., 2011; Guo et al., 2012). However, the lower body weight and fat mass at study endpoint compared to controls is not entirely reflective of obese T2DM (Lin et al., 2018; Bai et al., 2019), but rather as a model of T2DM, an emerging clinical feature in many diabetic populations (Balasubramanyam et al., 2011; Florez and Castillo-Florez, 2012).

T2DM-associated vascular dysfunction is a major clinical problem that is linked with a higher incidence of coronary artery, peripheral vascular and microvascular disease (Laakso, 1999; Eleftheriadou et al., 2019). Endothelial dysfunction has been defined as a common biomarker of diabetes (Iellamo et al., 2006; Vanhoutte et al., 2017), with compromised signaling of endothelium-derived relaxing factors playing a major role. Endothelial dysfunction has been well-characterized in the STZ-induced model of experimental type 1 diabetes mellitus (T1DM) (Makino et al., 2000; Matsumoto et al., 2003) as well as in db/db mice, which are spontaneously diabetic as a result of inherited gene mutation (Pannirselvam et al., 2002; Gao et al., 2010; Lee et al., 2011; Park et al., 2011). In the present study, carotid arteries isolated from HFD plus STZ-induced diabetic rats exhibited impaired endothelium-dependent relaxation in response to ACh. By contrast, the response to the endothelium-independent vasodilator, SNP, was not affected by diabetes, indicating that vascular smooth muscle function was intact. Thus, endothelial function was selectively impaired by diabetes, suggesting that endothelial cells are more vulnerable than smooth muscle cells to diabetes-induced impairment. These observations are consistent with other studies that have demonstrated that diabetes causes endothelial dysfunction but does not affect smooth muscle function, in either conduit or resistance vasculature (Leo et al., 2011; Kahlberg et al., 2016).

In order to evaluate nitrogen oxide-mediated relaxation, EDH-induced relaxation was inhibited by IKCa and SKCa.
channel blockers, apamin and TRAM-34, respectively. Thus, the residual vascular relaxation response to ACh was attributed to nitrogen oxide species (i.e. NO• and HNO). We observed here that endothelium-dependent relaxation was not affected by the presence of KCa blockers in either sham or diabetic carotid arteries, indicating that endothelium-derived nitrogen oxide species are the main contributors to endothelium-dependent vasodilatation in large conduit carotid arteries. This observation is consistent with several other studies (Joannides et al., 1995; Woodman et al., 2000; Takaki et al., 2008; Feletou et al., 2012).

In addition, similar observations have been made in the SNP-mediated relaxation in the current study. We found that the vasorelaxation response to SNP was only affected by the presence of the NOS inhibitor plus sGC inhibitor (L-NAME + ODQ) in both sham and diabetic carotid arteries, demonstrating that nitrogen oxide species acting on sGC are the predominant dilator mechanisms of SNP-induced relaxation in the carotid arteries.

To examine whether EDH contributed to endothelium-dependent relaxation of carotid arteries in diabetes, the combination of L-NAME and ODQ were used to inhibit NOS and sGC activities, respectively. The presence of L-NAME and ODQ (and the cyclooxygenase inhibitor-indomethacin) abolished the ACh-induced vasodilatation response in diabetic as well as sham rats, but not the KCa blockers, indicating that EDH does not contribute to endothelium-dependent relaxation in carotid arteries. It has been reported that the contribution of EDH to endothelium-dependent relaxation is predominantly found in resistance arteries (i.e. small arteries with diameters of less than 500 μM) (Mulvany and Aalkjær, 1990; Tomioka et al., 1999; Shimokawa and Godo, 2016; Garland and Dora, 2017) and more likely to be preserved, or even upregulated, to compensate for the loss of NO•-mediated relaxation in a disease state, such as diabetes (Cho et al., 2013; Kobuchi et al., 2015; Mokhtar et al., 2016a; Mokhtar et al., 2016b). Whereas it has been reported that EDH may play a role in the carotid in diabetes as there is increased expression of IKCa and a contribution of EDH early in the disease process in carotid arteries from diabetic animals (Leo et al., 2010; Centeno et al., 2019). In contrast, in this study with more advanced diabetes there was no compensation from EDH for diabetes-induced impairment of endothelium-dependent relaxation in the carotid artery, which is consistent with a previous study (Shi et al., 2006).

To investigate the potential role of endogenous HNO as an endothelium-derived vasodilator in carotid arteries, we employed the well-characterized pharmacological tools, t-cysteine (HNO scavenger) (Pino and Feelisch, 1994; Ellis et al., 2000; Irvine et al., 2003; Andrews et al., 2009) and HXC (NO• scavenger) (Li and Rand, 1993; Wanstaff et al., 2005; Andrews et al., 2009). In the current study, we provide evidence that both endogenous, eNOS-derived NO• and HNO exist in carotid arteries from sham or diabetic rats. These findings confirm that the endogenous eNOS-derived NO• and HNO are both released in the conduit vasculature. This observation is consistent with a recent study that demonstrated that there was endogenous eNOS-derived nitrogen oxide (NO• and HNO) present in resistance vessels (Kahlberg et al., 2016).

We demonstrated that in the presence of either HXC or t-cysteine, the maximal relaxation response to ACh was decreased when compared to control arteries. Such observations indicate that both NO• and HNO contribute to ACh-induced relaxation in carotid arteries from sham rats. The HNO scavenger t-cysteine also attenuated ACh-induced maximal relaxation in the diabetic vasculature, whereas the NO• scavenger HXC did not. Further, we observed a significant reduction in the basal level of NO• as a result of diabetes evidenced by a significant reduction in HXC-induced contraction in carotid arteries from diabetic compared to sham rats. In contrast, there was no difference in the basal level of HNO between the sham and diabetic group as t-cysteine-induced contraction was not changed. Together these findings suggest that the bioavailability of endogenous NO• and NO•-mediated relaxation was impaired in diabetes, whereas the component of HNO is preserved in the context of experimental diabetes. Additionally, as mentioned previously, there was a significant reduction in the basal release of NO• as a result of diabetes. In contrast, there was no difference in the contractile response to either inhibition of basal HNO or nitrogen oxide release between the two groups. This may be due HNO scavenger that was employed in the present study (i.e. t-cysteine), which may not only attenuate HNO but also enhance and prolong the actions of NO• (Pino and Feelisch, 1994; Ellis et al., 2000; Wanstaff et al., 2001) and thus may increase endogenous NO• bioavailability along with a loss of endogenous HNO.

The major mechanism implicated in diabetes-induced endothelial dysfunction includes increased oxidative stress and compromised NO• signaling (De Vriese et al., 2000; Fatehi-Hassanabad et al., 2010; Leo et al., 2010; Leo et al., 2011). The impairment of NO•-mediated relaxation in the diabetic vasculature occurs through several pathways including a deficiency in L-arginine or BH4 levels. This critical substrate and cofactor, respectively, are required for NO• synthesis by eNOS (Boucher et al., 1999; Luiking et al., 2010). Decreased levels of L-arginine or BH4 can lead to uncoupling of eNOS, which consequently results in the generation of ROS instead of NO• in the vasculature (Chang et al., 1993; Beckman and Koppenol, 1996). ROS such as •O2− reacts rapidly with NO• to produce peroxynitrite (ONOO•) (Paolocci et al., 2001), simultaneously increasing ONOO•-induced cellular toxicity (Beckman and Koppenol, 1996; Beckman and Zu Ye, 1996). It has been reported that peroxynitrite can lead to eNOS uncoupling through oxidation of BH4 to dihydrobiopterin (BH2), thus further promoting overproduction of •O2− (Zou et al., 2004). This overproduction of •O2− is likely an early feature of diabetic vascular disease, which contributes to impaired NO• synthesis/ activity and endothelial dysfunction (Guzik et al., 2002; Pennathur and Heinecke, 2007; Velagic et al., 2020). There is an accumulating body of evidence to demonstrate that NO•-mediated relaxation is impaired in diabetes. For example, several studies have demonstrated that endothelial
dysfunction is associated with a significant reduction in endothelium-dependent NO•-mediated relaxation in diabetic mesenteric arteries which was caused by increased oxidative stress (Makino et al., 2000; Matsumoto et al., 2003; Leo et al., 2011). In addition, in the db/db mouse model of T2DM, impaired NO•-mediated vasodilatation was observed in the coronary vasculature (Park et al., 2008).

Previous studies have also demonstrated that the contribution of HNO to endothelium-dependent relaxation is preserved in arteries from hypertensive mice (Wynne et al., 2012), T1DM rats (Leo et al., 2012; Kahlberg et al., 2016; Tare et al., 2017) and hypercholesterolaemic mice (Bullen et al., 2011; Jelinic et al., 2014) where oxidative stress is also evident. Pharmacological studies have provided evidence to suggest that HNO is resistant to scavenging by •O2− and lacks reactivity with •O2− to form ONOO− (Miranda et al., 2002; Leo et al., 2012), thus resulting in preserved HNO-mediated vasodilatation (Miranda et al., 2002). Furthermore, HNO itself can limit •O2− production by directly inhibiting vascular NADPH oxidase (Nox2) (Miller et al., 2009), supporting our results that endogenous generation and/or bioavailability of HNO is preserved in the large conduit artery in this model of diabetes. Our demonstration that, in the rat carotid artery, diabetes impairs relaxation to endogenous NO• whereas endogenous HNO activity is preserved provides further support to the proposal that HNO donors may prove more effective than classical NO• donors in the treatment of cardiovascular disease (Andrews et al., 2016; Chin et al., 2016; Qin et al., 2020). It has been previously demonstrated that in diabetes, and other causes of oxidative stress, there is impairment of vascular and cardiac responses to NO• donors (Van Etten et al., 2002; Okon et al., 2005; Shemyakin et al., 2012; Qin et al., 2020) referred to as NO• resistance. Further, while tolerance to the chronic use of NO• donors is a well-established phenomenon, HNO donors maintain their efficacy with continued use (Irvine et al., 2007; Kemp-Harper, 2011; Dautov et al., 2013; Tare et al., 2017). Efforts are underway to develop new generation HNO donors with optimal half-lives to enhance their therapeutic utility (Cowart et al., 2019). Although the current studies are directed toward their potential use in congestive heart failure. Our study suggests that it may be worthwhile investigating their vascular-protective effects in diabetes.

The relative contribution of NO• and HNO to SNP-induced relaxation was also investigated. Interestingly, we found that sensitivity to SNP in rat carotid arteries was impaired by both HXC and L-cysteine, indicating that both NO• and HNO can be released from SNP. This finding is in agreement with those of other investigators (Ellis et al., 2000; Irvine et al., 2003). In addition, there is no significant differences between sham and diabetic vessels for the same inhibitors used, suggesting that exogenous nitrogen oxide (either NO• or HNO) was not affected by diabetes, though endogenous nitrogen oxide could be reduced in the disease state. This observation strengthens the concept that the release of NO• from the endothelium is impaired by diabetes rather than the action of NO• on the smooth muscle.

Limitations of the Study
Despite the findings obtained regarding the likely effect of diabetes on endogenous NO• and HNO-mediated relaxation and their basal level in carotid arteries, there are limitations of the current study that should be noted. In this study, we investigated the effect of L-cysteine and HXC individually on the relaxation response to ACh, but not the impact of both inhibitors in combination. While in our earlier studies, we have assessed the combined effects of HXC + L-cysteine in the rat aorta (Leo et al., 2012), femoral arteries (Tare et al., 2017) and mesenteric arteries (Kahlberg et al., 2016). In all vessels, the combination of HXC + L-Cysteine abolished NO/HNO mediated relaxation to a similar extent as NOS inhibition. Moreover, it is also important to note, however, that definitive evidence for endogenous production of HNO could not be acquired in the present study, since there remains a lack of validated methods to measure HNO at the tissue level (Kahlberg et al., 2016).

CONCLUSION
In conclusion, we have confirmed that nitrogen oxide species (NO• and HNO) are the major contributors to endothelium-dependent relaxation in the rat carotid artery, with no contribution by EDH. Importantly, this study has demonstrated that diabetes impairs NO•-mediated vasorelaxation and basal release of NO•, while the HNO-mediated vasorelaxation is preserved, as is basal HNO release. The preservation of HNO bioavailability found in this study indicates that there is a potential for HNO donors to be employed as therapeutic agents for the treatment of vascular dysfunction associated with diabetes.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT
The animal study was reviewed and approved by Alfred Medical Research Educational Precinct (AMREP) Animal Ethics Committee.

AUTHOR CONTRIBUTIONS
OLW, RHR, and CXQ conceived and designed the research. JCL and AV performed the experiments. JCL, AV, and ML collected and analyzed the data. JCL and OLW interpreted the data. JCL prepared the figures and drafted the manuscript. JCL, AV, CXQ, ML, CHL, BKK, RHR, and OLW edited and revised the manuscript. All authors approved the final version of the manuscript.
FUNDING

This work was supported in part by the National Health and Medical Research Council (NHMRC) of Australia (to RHR and BKK, APP1120859). Diabetes Australia Research Trust Y13M1-RITR (to RHR and BKK) and the Victorian Government’s Operational Infrastructure Support Program. RHR was an NHMRC Senior Research Fellow (APP1059960). QX received a National Heart Foundation Future Leader Fellowship. AV is supported by a Research Training Program (RTP) Scholarship and a Monash Graduate Excellence Scholarship (MGES) provided by Monash University.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2020.585740/full#supplementary-material.

REFERENCES

Adak, S., Wang, Q., and Stuehr, D. J. (2000). Arginine conversion to nitroxy by tetrahydrobiopterin-free neuronal nitric-oxide synthase. Implications for mechanism. J. Biol. Chem. 275, 33554–33561. doi:10.1074/jbc.M004337200
Albersen, M., Lin, G., Fandel, T. M., Zhang, H., Qiu, X., Lin, C. S., et al. (2011). Functional, metabolic, and morphologic characteristics of a novel rat model of type 2 diabetes-associated erectile dysfunction. Urology 78, 476–478. doi:10.1016/j.urology.2011.03.024
Andrews, K. L., Irvine, J. C., Tare, M., Apostolopoulos, J., Favaloro, J. L., Triggie, C. R., et al. (2009). A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries. Br. J. Pharmacol. 157, 540–550. doi:10.1111/j.1476-5381.2009.00150.x
Andrews, K. L., Sampson, A. K., Irvine, J. C., Shihata, W. A., Michell, D. L., Lumsden, N. G., et al. (2016). Nitroxyl (HNO) reduces endothelial and monocyte activation and promotes M2 macrophage polarization. Clin. Sci. 130, 1629–1640. doi:10.1042/CS20160097
Asrafuzzaman, M., Cao, Y., Afroz, R., Kamato, D., Gray, S., and Little, P. J. (2017). Animal models for assessing the impact of natural products on the aetiology and metabolic pathophysiology of Type 2 diabetes. Biomed. Pharmacother. 89, 1242–1251. doi:10.1016/j.biopharm.2017.03.010
Bai, B., Yang, W., Fu, Y., Foon, H. L., Tay, W. T., Yang, K., et al. (2019). Seisin hydrogen sulfothiolation prevents ischaemia–reperfusion injury in the rat heart ex vivo. Phosphoryl. Res. 104, 165–175. doi:10.1016/j.phrs.2015.12.006
Cho, Y. E., Basu, A., Dai, A., Heldak, M., and Makino, A. (2013). Coronary endothelial dysfunction and mitochondrial reactive oxygen species in type 2 diabetic mice. Am. J. Physiol. Cell Physiol. 305, C1033–C1040. doi:10.1152/ajpcell.00234.2013
Coleman, H., Tare, M., and Parkinson, H. (2017). Nonlinear effects of potassium channel blockers on endothelium-dependent hyperpolarization. Acta Physiol. 219, 324–334. doi:10.1111/apha.12805
Cowart, D., Venuti, R. P., Lynch, K., Gupill, J. T., Noveck, R. J., and Foo, S. Y. (2019). A phase 1 randomized study of single intravenous infusions of the novel nitroxyl donor BMS-986231 in healthy volunteers. J. Clin. Pharmacol. 59, 717–730. doi:10.1002/jcph.1364
Dautov, R., Ngo, D., Licari, G., Liu, S., Sverdlov, A. L., Ritchie, R. H., et al. (2013). The nitric oxide reductase sibiling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness. Nitric Oxide 35, 72–78. doi:10.1016/j.niox.2013.08.006
De Vriese, A. S., Verbeuren, T. J., Van De Voorde, J., Lameire, N. H., and Vanhoute, P. M. (2000). Endothelial dysfunction in diabetes. Br. J. Pharmacol. 130, 963–974. doi:10.1038/sj.bjp.0703393
Dempsey, R. J., Vemuganti, R., Varghese, T., and Hermann, B. P. (2010). A review of carotid atherosclerosis and vascular cognitive decline: a new understanding of the keys to symptomology. Neurosurgery. 67, 484. doi:10.1227/01.NEU.0000371370.11404.36
Ding, S., Zhang, M., Zhao, Y., Chen, W., Yao, G., Zhang, C., et al. (2008). The role of carotid plaque vulnerability and inflammation in the pathogenesis of acute ischemic stroke. Am. J. Med. Sci. 336, 27–31. doi:10.1097/MAJ.0b013e3181b36f01
Douglas, G., and Channon, K. M. (2014). The pathogenesis of atherosclerosis. Medicine 42, 480–484.
Dutton, A. S., Fukuto, J. M., and Houk, K. (2004). Mechanisms of HNO and NO production from Angelii’s salt: density functional and CBS-QB3 theory predictions. J. Am. Chem. Soc. 126, 3795–3800. doi:10.1021/ja0391614
Eleftheriadou, I., Tentolouris, A., Grigoropoulou, P., Tsilinigris, D., Anastasiou, I., Kokkinos, A., et al. (2019). The association of diabetic microvascular and macrovascular disease with cutaneous circulation in patients with type 2 diabetes mellitus. J. Diabet. Complicat. 33, 165–170. doi:10.1016/j.jdiacomp.2018.10.008
Ellis, A. J., Li, C., and Rand, M. J. (2000). Differential actions of L-cysteine on responses to nitric oxide, nitrosyl anions and EDRF in the rat aorta. Br. J. Pharmacol. 129, 315–322. doi:10.1038/sj.bjp.0703058
Endemann, D. H., and Schiffrin, E. L. (2004). Endothelial dysfunction. J. Am. Soc. Nephrol. 15, 1983–1992. doi:10.1097/01.ASN.0000132474.50966.DA
Feitahi-Hassanabad, Z., Chan, C. B., and Furman, B. L. (2010). Reactive oxygen species and endothelium function in diabetes. Eur. J. Pharmacol. 636, 8–17. doi:10.1016/j.ejphar.2010.03.048
Félotou, M., Köhler, S., and Vanhoutte, P. M. (2012). Nitric oxide oxidizer of endothelium-dependent responses. Ann. Med. 44, 694–716. doi:10.3109/07853890.2011.585658
Florez, H., and Castillo-Florez, S. (2012). Beyond the obesity paradox in diabetes: fitness, fatness, and mortality. Jama. 308, 619–620. doi:10.1001/jama.2012.9776
Fowler, M. J. (2008). Microvascular and macrovascular complications of diabetes. Clin. Diabetes 26, 77–82. doi:10.4103/2230-8210.183480
Van Etten, R., De Koning, E., Gaillard, C., and Rabelink, T. (2002). Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate. *Diabetologia* 45, 1004–1010. doi:10.1007/s00125-002-0862-1

Vanhoutte, P., Shimokawa, H., Feletou, M., and Tang, E. (2017). Endothelial dysfunction and vascular disease - a 30th anniversary update. *Acta Physiol.* 219, 22–96. doi:10.1111/apha.12646

Velagic, A., Qin, C., Woodman, O. L., Horowitz, J. D., Ritchie, R. H., and Kemp-Harper, B. K. (2020). Nitroxyl: a novel strategy to circumvent diabetes associated impairments in nitric oxide signaling. *Front. Pharmacol.* 11, 727. doi:10.3389/fphar.2020.00727

Wanstall, J. C., Homer, K. L., and Doggrel, S. A. (2005). Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets. *Curr. Vasc. Pharmacol.* 3, 41–53. doi:10.2174/1570161052773933

Wanstall, J. C., Jeffery, T. K., Gambino, A., Lovren, F., and Triggle, C. R. (2001). Vascular smooth muscle relaxation mediated by nitric oxide donors: a comparison with acetylcholine, nitric oxide and nitroxy ion. *Br. J. Pharmacol.* 134, 463–472. doi:10.1038/sj.bjp.0704269

Wigg, S. J., Tare, M., Tonta, M. A., O’Brien, R. C., Meredith, I. T., and Parkington, H. C. (2001). Comparison of effects of diabetes mellitus on an EDHF-dependent and an EDHF-independent artery. *Am. J. Physiol. Heart Circ. Physiol.* 281, H232–H240. doi:10.1152/ajpheart.2001.281.1.H232

Woodman, O. L., Wongsawatskul, O., and Soeby, C. G. (2000). Contribution of nitric oxide, cyclic GMP and K+ channels to acetylcholine-induced dilatation of rat conduit and resistance arteries. *Clin. Exp. Pharmacol. Physiol.* 27, 34–40. doi:10.1046/j.1440-1681.2000.03199.x

Wynne, B. M., Labazi, H., Tostes, R. C., and Webb, R. C. (2012). Aorta from angiotensin II hypertensive mice exhibit preserved nitroxyl anion mediated relaxation responses. *Pharmacol. Res.* 65, 41–47. doi:10.1016/j.phrs.2011.07.002

Zardi, E. M., and Afeltra, A. (2010). Endothelial dysfunction and vascular stiffness in systemic lupus erythematous: are they early markers of subclinical atherosclerosis?. *Autoimmun. Rev.* 9, 684–686. doi:10.1016/j.autrev.2010.05.018

Zhang, M., Lv, X. Y., Li, J., Xu, Z. G., and Chen, L. (2008). The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. *Exp. Diabetes Res.*, 2008, 704045. doi:10.1155/2008/704045

Zou, M.-H., Cohen, R. A., and Ullrich, V. (2004). Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Abingdon, United Kingdom: Taylor & Francis.

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Li, Velagic, Qin, Li, Leo, Kemp-Harper, Ritchie and Woodman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
GLOSSARY

ACh acetylcholine
BH4 tetrahydrobiopterin
Ca2+ calcium
COX cyclooxygenase
DMSO dimethyl sulfoxide
EDH endothelium-dependent hyperpolarization
eNOS endothelial nitric oxide synthase
GTT glucose tolerance test
HFD high fat diet
HNO nitroxyl
HXC hydroxocobalamin
IKCa, intermediate-conductance Ca2+-activated K+ channel
KCa, calcium-activated potassium channel
KPSS, high K+-containing physiological saline solution
L-Cys L-cysteine
L-NAME Nω-nitro-L-arginine methyl ester
NO nitric oxide
Nox2 NADPH oxidase 2
•O2− superoxide
ODQ 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one
ONOO− peroxynitrite
PE phenylephrine
pEC50 negative log of half-maximal effective concentration
Rmax maximum relaxation
ROS reactive oxygen species
SD Sprague Dawley
sGC soluble guanylate cyclase
SKCa, small-conductance Ca2+-activated K+ channel
SNP sodium nitroprusside
STZ streptozotocin
T2DM type 2 diabetes mellitus
TRAM-34 1-[(2-chlorophenyl)(diphenyl)methyl]-1H-pyrazole
U46619 9, 11-dideoxy-9α, 11α-methanoepoxy-PGF2α.